Capmatinib (Capatinib) manufacturers and latest price information

Capatinib (Capatinib), as a targeted therapy for non-small cell lung cancer (NSCLC) carrying mesenchymal epithelial transition factor (MET) exon 14 skipping mutations, has attracted much attention in recent years. Its core manufacturer is the Swiss company Novartis, which enjoys a high reputation in the global pharmaceutical field and is known for its research and development of innovative drugs.

Capmatinib is an innovation of Novartis Pharmaceuticals, with the trade nameTabrecta. Since it was approved for sale by the U.S. Food and Drug Administration (FDA) in 2020, it has been widely used in clinical treatments around the world. Its unique tyrosine kinase inhibition mechanism can precisely act on the MET receptor and significantly inhibit the growth of diseased cells caused by specific genetic mutations, providing a new treatment option for patients with advanced or metastatic non-small cell lung cancer.

In terms of price, capmatinib is relatively expensive because of its excellent clinical efficacy and unique research and development costs. There are certain differences in the price of capmatinib in different specifications and in different regions. For example, in overseas markets, the price of the Hong Kong version of capmatinib (200mg*60 tablets) is about 30,000 to 40,000 yuan per box, while the price of the generic version of the same specification drug produced by Lucius Pharmaceuticals in Laos may be slightly lower, about 3,000 yuan per box. However, these prices are for reference only, and actual purchases may fluctuate due to market supply, production costs, import taxes, policy adjustments and other factors.

To sum up, capmatinib (capatinib), as an innovation of Novartis Pharmaceuticals, plays an important role in the treatment of non-small cell lung cancer. Its manufacturers are strong, and prices vary depending on versions and regions. In the future, with the continuous development and improvement of the pharmaceutical market, capmatinib is expected to benefit more patients.